peripheral nervous system disease: A disease involving the peripheral nervous system.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
231 |
4. Check minimum number of eventsNone |
231 |
5. Include endpointsNone |
231 |
6. Filter based on genotype QC (FinnGen only) |
224 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G60-G64
- Name in latin
- Aliae morbositates systematis nervosi peripherici
Similar endpoints
↥List of similar endpoints to
Other disorders of peripheral nervous system
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1252 | 584 | 661 |
| Only index persons | 1109 | 536 | 573 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 59.48 | 59.38 | 59.73 |
| Only index persons | 57.53 | 58.02 | 57.07 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 224 | 119 | 105 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.05 |
| Median age at first event (years) | 59.15 | 56.79 | 61.82 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 231
- Matched controls
- 2310
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G64
ICD-10 Finland
Other disorders of peripheral nervous system
+∞
307.7
230
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
108.3
48.1
51
6
N03AX12
ATC
[U] gabapentin; oral
5.8
36.2
91
231
N03AX16
ATC
[U] pregabalin
4.8
30.3
104
336
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.7
20.8
36
62
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.4
20.2
45
99
N06AX21
ATC
duloxetine; oral
4.6
19.8
57
155
G62.8
ICD-10 Finland
Other specified polyneuropathies
194.3
17.8
18
*
TAB00
NOMESCO Finland
Lumbar puncture
6.0
16.4
31
58
N02BF02
ATC
pregabalin; oral
6.1
16.2
30
55
R20.2
ICD-10 Finland
Paraesthesia of skin
5.1
16.1
37
83
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.1
14.3
44
124
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.8
13.1
108
553
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.5
12.3
25
50
L28
ICPC
Limited function/disability (L)
3.1
11.8
59
228
N03AE01
ATC
clonazepam; systemic
4.7
10.3
25
58
AA1AD
NOMESCO Finland
CT of head and brain
2.6
10.2
83
412
N02AX02
ATC
tramadol; systemic, rectal
2.4
10.0
122
727
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.5
9.7
36
115
R42
ICD-10 Finland
Dizziness and giddiness
2.6
9.3
68
319
R52.2
ICD-10 Finland
Other chronic pain
5.1
8.8
19
40
N06AX11
ATC
mirtazapine; oral
2.3
8.7
96
541
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.7
8.6
52
221
M79.6
ICD-10 Finland
Pain in limb
2.3
8.5
114
695
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.4
8.4
32
104
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
8.2
82
440
N06AA09
ATC
amitriptyline; systemic
3.1
7.8
34
120
H02AB06
ATC
prednisolone; systemic
2.2
7.7
127
830
N02BF01
ATC
gabapentin; oral
3.3
7.7
31
104
N99
ICPC
Neurological disease other
19.2
7.7
11
6
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
7.7
122
787
A01
ICPC
Pain general/multiple sites
3.2
7.5
32
111
J45.9
ICD-10 Finland
Asthma, unspecified
2.5
7.4
57
271
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
+∞
7.3
7
*
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
+∞
7.3
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
7.1
60
297
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
7.1
74
401
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
7.0
80
449
A28
ICPC
Limited function/disability NOS
2.5
7.0
52
243
M54.5
ICD-10 Finland
Low back pain
2.1
6.8
92
550
A04
ICPC
Weakness/tiredness general
2.6
6.7
41
174
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
9.1
6.6
13
15
ACC51
NOMESCO Finland
Release of median nerve
3.5
6.6
24
75
N06AX16
ATC
venlafaxine; oral
2.6
6.6
41
175
R52.9
ICD-10 Finland
Pain, unspecified
2.9
6.3
32
123
H02AB07
ATC
prednisone; oral
2.6
6.2
39
168
N28
ICPC
Limited function/disability (N)
13.0
6.1
10
8
R02
ICPC
Shortness of breath/dyspnoea
2.6
6.1
38
162
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.0
6.1
29
107
M48.0
ICD-10 Finland
Spinal stenosis
2.6
6.1
39
169
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.3
6.1
54
272
R4110
NOMESCO Finland
Physiotherapy
2.1
6.0
75
432
R5110, ,
SPAT
3.6
6.0
20
59
N03AX09
ATC
lamotrigine; oral
4.2
6.0
16
40
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
52
118
5.40
22.62
2.4
2.4
—
15.54
—
0
7
47
102
5.53
21.43
1.3
1.3
—
31.40
—
0
9
36
67
6.18
19.23
3.2
1.3
—
—
—
0
0
135
728
3.06
15.50
2.4
1.9
94.86
94.98
pmol/l
0.01
76
366
113
573
2.90
14.18
2.6
2.0
204.65
198.92
u/l
0.03
105
537
133
807
2.53
10.75
5.8
4.3
35.54
35.62
g/l
0.06
125
754
136
834
2.53
10.74
11.2
5.8
1.22
1.21
mmol/l
0.09
129
755
21
41
5.53
10.53
1.2
1.2
5.13
159.72
e6/l
0.54
15
32
21
41
5.53
10.53
1.2
1.1
1.47
2.79
e6/l
1.14
15
29
15
8
19.94
10.40
1.2
1.0
—
—
—
0
0
141
910
2.41
9.52
7.9
6.9
1.22
1.21
mmol/l
0.22
123
771
159
1089
2.48
9.30
10.6
10.0
4.23
4.13
e9/l
0.21
143
949
79
398
2.50
9.27
1.3
1.2
1.78
1.63
u/ml
0.04
12
115
63
287
2.64
9.09
4.3
3.3
0.79
0.82
mmol/l
1.46
57
267
16
17
10.02
8.42
1.2
1.1
—
—
—
0
0
149
1017
2.31
8.40
7.6
6.6
10.40
11.33
umol/l
0.88
144
962
83
448
2.33
8.20
1.9
1.6
19.88
20.93
nmol/l
0.28
75
378
15
15
10.60
8.16
1.1
1.1
—
—
—
0
0
80
429
2.32
8.00
2.6
2.0
2.44
3.34
mg/l
3.82
71
367
48
209
2.64
7.48
1.8
1.6
—
—
—
0
0
167
1228
2.30
7.43
5.3
4.3
—
365.52
—
0
21
46
197
2.67
7.40
2.5
5.1
243.32
245.97
u/l
0.05
41
186
14
15
9.85
7.39
1.2
1.0
—
—
—
0
0
114
730
2.11
7.15
2.5
2.2
78.68
76.51
nmol/l
0.34
102
643
102
630
2.11
7.00
4.2
3.4
2.35
2.36
mmol/l
0.37
92
549
179
1396
2.25
6.29
5.9
4.1
13.29
11.89
mm/h
0.60
171
1276
46
213
2.45
6.26
1.8
1.7
—
—
—
0
0
58
304
2.21
5.92
1.9
1.8
—
—
—
0
0
129
906
1.96
5.87
18.6
12.9
1.23
1.28
inr
0.25
38
257
114
768
1.96
5.86
3.6
2.6
131.96
129.99
ug/l
0.03
108
697
63
345
2.14
5.75
1.7
1.7
1078.92
1238.65
nmol/l
0.67
54
256
165
1278
2.02
5.46
3.8
3.0
54.67
47.00
u/l
0.39
156
1195
49
248
2.24
5.41
2.4
2.3
23.42
22.78
%
0.12
42
209
38
172
2.45
5.40
2.7
2.3
84.23
30.10
u/l
0.46
30
145
19
60
3.36
5.17
1.3
1.9
—
—
—
0
0
56
305
2.10
5.13
3.6
2.6
0.81
0.87
e6/l
0.07
33
170
67
399
1.96
4.78
1.8
1.6
0.97
1.25
mg/l
0.58
47
317
94
626
1.85
4.76
4.5
3.3
32.98
29.75
u/l
0.43
88
597
15
35
4.51
4.72
1.1
1.3
—
—
—
0
0
15
35
4.51
4.72
1.1
1.3
—
—
—
0
0
82
526
1.87
4.65
4.1
2.8
0.50
0.35
e6/l
0.40
70
392
33
151
2.38
4.57
5.0
6.5
8.41
9.53
mmol/l
0.44
33
143
52
288
2.04
4.52
3.9
2.9
3.34
2.31
e6/l
0.29
29
157
14
41
3.57
4.25
1.2
1.3
—
—
—
0
0
15
47
3.34
4.13
1.4
1.4
7.69
1.56
u/ml
—
7
11
65
405
1.84
3.96
1.7
1.8
410.12
441.06
pmol/l
0.51
57
333
96
673
1.73
3.92
4.4
3.0
—
—
—
0
0
24
102
2.51
3.89
1.3
1.3
—
—
—
0
0
90
627
1.71
3.72
2.9
2.3
49.78
55.38
u/l
1.25
85
581
124
942
1.68
3.70
3.8
3.7
0.00
0.00
estimate
-0.00
20
165
64
405
1.80
3.69
3.4
4.0
1.02
1.02
kg/l
0.15
14
52
122
931
1.66
3.51
4.9
4.9
0.00
0.00
estimate
-0.00
21
173
6
6
10.22
3.51
1.2
1.0
—
—
—
0
0
170
1416
1.76
3.51
3.9
3.9
15.17
14.88
pmol/l
0.73
154
1276
199
1741
2.03
3.49
5.2
4.6
1.63
1.92
mu/l
3.70
185
1582
24
109
2.34
3.39
1.7
1.6
—
—
—
0
0
57
358
1.79
3.34
7.6
3.4
407.57
153.28
ng/l
0.59
46
280
101
751
1.61
3.12
4.9
3.7
74.28
36.50
ng/l
0.39
74
524
6
8
7.66
3.07
1.0
1.4
1.97
2.00
mmol/l
—
6
8
51
322
1.75
2.91
1.4
1.3
29.01
36.13
iu/ml
0.22
15
99
115
896
1.56
2.84
3.2
2.5
—
—
—
0
0
118
927
1.56
2.80
3.7
3.7
0.00
0.01
estimate
0.50
21
186
5
6
8.48
2.76
1.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
10
6.12
2.71
1.0
1.2
—
—
—
0
0
208
1894
1.99
2.56
24.3
13.8
23.35
22.88
mg/l
0.08
182
1499
5
7
7.27
2.56
1.0
1.1
—
—
—
0
0
65
459
1.58
2.40
3.0
2.2
—
—
—
0
0
36
218
1.77
2.37
15.5
7.7
1.98
1.14
mmol/l
0.59
28
174
13
53
2.54
2.32
1.6
1.5
306.25
300.25
ug/g
—
8
29
78
580
1.52
2.27
4.4
3.8
11.48
7.44
mg/mmol
0.34
48
357
5
9
5.65
2.22
1.0
1.2
—
—
—
0
0
17
81
2.19
2.19
2.5
1.7
—
—
—
0
0
29
169
1.82
2.16
2.3
3.7
5.88
5.74
kpa
0.38
29
163
14
62
2.34
2.12
3.4
2.8
—
—
—
0
0
15
69
2.26
2.09
2.3
1.6
—
—
—
0
0
14
63
2.30
2.05
1.6
1.4
—
—
—
0
0
35
224
1.66
1.90
15.3
6.8
105.34
104.12
mmol/l
1.31
35
224
67
499
1.48
1.90
2.1
2.8
330.68
8019.73
umol/l
2.44
60
430
201
1848
1.68
1.89
4.8
4.7
6.13
5.98
mmol/l
0.63
189
1684
14
66
2.19
1.86
2.0
1.5
—
—
—
0
0
6
17
3.59
1.85
1.2
1.2
—
—
—
0
0
6
17
3.59
1.85
1.3
3.7
—
—
—
0
0
44
301
1.57
1.84
1.3
1.3
1.24
11.29
u/ml
1.45
15
106
215
2019
1.94
1.80
28.6
16.4
75.11
77.63
umol/l
0.84
215
2019
134
1144
1.41
1.77
3.3
2.9
—
—
—
0
0
7
25
2.85
1.66
1.1
1.1
—
—
—
0
0
67
513
1.43
1.63
1.6
1.7
1.47
1.37
mmol/l
0.49
62
423
10
45
2.28
1.48
1.0
1.4
—
—
—
0
0
89
726
1.37
1.48
3.3
3.8
—
—
—
0
0
5
16
3.17
1.44
1.4
1.3
—
—
—
0
0
5
16
3.17
1.44
2.0
1.9
—
—
—
0
0
24
151
1.66
1.41
3.0
3.0
56.11
60.18
ml/min/173m2
—
9
66
6
23
2.65
1.37
1.3
1.1
—
—
—
0
0
11
54
2.09
1.35
1.1
1.2
—
—
—
0
0
9
43
2.14
1.32
1.2
1.1
—
—
—
0
0
33
229
1.51
1.31
4.2
4.5
28.69
26.57
ug/l
0.02
26
187
8
34
2.40
1.30
1.9
6.4
—
150.50
—
0
6
5
18
2.82
1.29
1.0
1.3
—
—
—
0
0
9
44
2.09
1.28
1.1
1.7
—
—
—
0
0
194
1810
1.45
1.25
21.9
12.9
80.34
80.60
ml/min/173m2
0.06
165
1504
8
36
2.27
1.25
1.1
1.1
—
—
—
0
0
8
36
2.27
1.25
1.6
1.6
—
—
—
0
0
10
49
2.09
1.24
1.0
1.1
—
—
—
0
0
22
141
1.62
1.22
2.2
2.8
4.68
4.33
kpa
0.32
22
136
16
94
1.75
1.21
2.1
2.6
0.64
0.66
%
0.08
16
94
8
38
2.14
1.19
2.3
1.6
—
—
—
0
0
6
26
2.34
1.19
1.2
1.6
—
—
—
0
0
63
506
1.34
1.13
4.0
3.9
0.00
0.00
estimate
-0.00
21
170
7
31
2.30
1.11
1.1
1.3
—
—
—
0
0
20
129
1.60
1.10
1.6
1.6
—
—
—
0
0
5
21
2.41
1.09
3.4
2.9
—
—
—
0
0
16
99
1.66
1.03
2.1
2.5
1.73
1.17
%
1.04
16
99
191
1796
1.37
1.00
6.4
5.8
40.51
40.11
mmol/mol
0.21
184
1673
5
23
2.20
0.98
1.4
1.2
—
—
—
0
0
20
134
1.54
0.95
4.8
3.2
5.06
5.04
kpa
0.07
20
129
20
134
1.54
0.95
2.2
3.8
73.83
80.23
ng/l
0.18
14
114
6
27
2.25
0.94
1.2
1.6
—
—
—
0
0
6
27
2.25
0.94
1.2
1.6
—
—
—
0
0
6
27
2.25
0.94
1.2
1.6
—
—
—
0
0
6
27
2.25
0.94
1.2
1.6
—
—
—
0
0
6
28
2.17
0.92
1.2
1.6
—
—
—
0
0
6
29
2.10
0.90
2.0
1.3
—
—
—
0
0
8
43
1.89
0.88
1.3
1.3
—
—
—
0
0
6
30
2.03
0.87
1.0
1.1
—
28.88
—
0
8
8
46
1.77
0.83
1.1
1.5
—
—
—
0
0
8
48
1.69
0.79
1.1
1.7
—
—
—
0
0
15
99
1.55
0.77
1.0
1.0
—
—
—
0
0
5
24
2.11
0.75
1.6
1.6
15.00
19.10
ug/l
—
5
24
9
55
1.66
0.74
1.1
1.7
—
—
—
0
0
5
26
1.94
0.71
1.0
1.4
—
—
—
0
0
217
2107
1.49
0.71
34.9
20.7
40.36
40.36
%
0.00
202
1978
8
49
1.65
0.62
1.1
1.4
—
—
—
0
0
62
536
1.21
0.61
3.6
4.5
21.34
21.60
%
0.05
24
257
0
23
0.00
0.58
0.0
1.9
—
—
—
0
0
12
168
0.70
0.52
1.6
1.7
—
—
—
0
0
7
50
1.41
0.45
1.0
1.1
—
3.37
—
0
7
8
56
1.44
0.43
1.5
1.8
291.00
322.66
mu/l
—
8
50
5
32
1.57
0.42
1.2
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
198
1927
1.19
0.38
5.3
5.1
2.62
2.77
mmol/l
1.72
188
1770
5
37
1.36
0.37
1.8
1.6
—
—
—
0
0
73
675
1.12
0.30
4.7
4.9
1.78
2.66
ug/l
0.85
67
599
194
1893
1.16
0.30
4.7
4.6
4.47
4.67
mmol/l
2.22
184
1752
27
232
1.19
0.30
9.7
7.9
—
—
—
0
0
193
1885
1.15
0.28
4.6
4.5
1.42
1.46
mmol/l
0.75
180
1737
15
180
0.82
0.25
3.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
3.5
—
—
—
0
0
0
10
0.00
0.21
0.0
3.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.17
0.21
1.2
1.2
0.73
0.94
nmol/l
—
5
36
43
396
1.11
0.20
2.6
2.9
0.63
0.76
ug/l
0.48
34
251
8
69
1.17
0.16
2.3
2.0
—
—
—
0
0
8
73
1.10
0.16
2.3
2.2
—
—
—
0
0
20
182
1.11
0.11
3.2
3.5
—
—
—
0
0
5
64
0.78
0.08
1.0
1.2
—
—
—
0
0
5
65
0.76
0.08
1.0
1.2
—
—
—
0
0
15
164
0.91
0.08
2.5
1.6
—
—
—
0
0
28
266
1.06
0.06
1.3
1.4
—
—
—
0
0
31
303
1.03
0.01
1.4
1.5
—
—
—
0
0
183
1823
1.02
0.01
4.4
4.1
1.26
1.30
mmol/l
0.45
173
1671
24
245
0.98
0.00
4.8
4.8
35.33
31.23
%
0.76
18
164
0
7
0.00
0.00
0.0
9.0
—
—
—
0
0
5
49
1.02
-0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
9
98
0.92
-0.00
5.3
2.9
11.44
46.47
u/ml
—
9
93
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
9
95
0.95
-0.00
1.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_PERIPHOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_PERIPHOTH | 1.811 [1.42, 2.32] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.162 |
During the follow-up period (1.1.1998 — 31.12.2019), 143 out of 508 females with G6_PERIPHOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_PERIPHOTH | 2.226 [1.7, 2.91] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 185 out of 563 males with G6_PERIPHOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_PERIPHOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.178% | 0.322% |
| 5 | 0.962% | 2.451% |
| 10 | 2.551% | 6.395% |
| 15 | 4.571% | 12.048% |
| 20 | 7.489% | 19.046% |
Relationships between endpoints
↥Index endpoint: G6_PERIPHOTH – Other disorders of peripheral nervous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data